These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 36341440)

  • 1. Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers.
    Feng Q; Sun B; Xue T; Li R; Lin C; Gao Y; Sun L; Zhuo Y; Wang D
    Front Immunol; 2022; 13():1025608. PubMed ID: 36341440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
    Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
    J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach.
    Entezam M; Sanaei MJ; Mirzaei Y; Mer AH; Abdollahpour-Alitappeh M; Azadegan-Dehkordi F; Bagheri N
    Life Sci; 2023 Apr; 318():121459. PubMed ID: 36720453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
    Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
    PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
    Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment.
    Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric Cancer CAR T-cell Target Antigen ID'd.
    Cancer Discov; 2021 Dec; 11(12):2954. PubMed ID: 34642170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer.
    Zhu H; Fang X; Tuhin IJ; Tan J; Ye J; Jia Y; Xu N; Kang L; Li M; Lou X; Zhou JE; Wang Y; Yan Z; Yu L
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2261-2274. PubMed ID: 35445870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T‑cell therapy for gastric cancer: Potential and perspective (Review).
    Long B; Qin L; Zhang B; Li Q; Wang L; Jiang X; Ye H; Zhang G; Yu Z; Jiao Z
    Int J Oncol; 2020 Apr; 56(4):889-899. PubMed ID: 32319561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials.
    Drougkas K; Karampinos K; Karavolias I; Gomatou G; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Kotteas E
    J Gastrointest Cancer; 2024 May; ():. PubMed ID: 38695995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer.
    Zhou Z; Li J; Hong J; Chen S; Chen M; Wang L; Lin W; Ye Y
    Front Immunol; 2022; 13():1002361. PubMed ID: 36618357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
    Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
    Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum: Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers.
    Feng Q; Sun B; Xue T; Li R; Lin C; Gao Y; Sun L; Zhuo Y; Wang D
    Front Immunol; 2022; 13():1082984. PubMed ID: 36618369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T cells: engineered immune cells to treat brain cancers and beyond.
    Huang Z; Dewanjee S; Chakraborty P; Jha NK; Dey A; Gangopadhyay M; Chen XY; Wang J; Jha SK
    Mol Cancer; 2023 Jan; 22(1):22. PubMed ID: 36721153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
    Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
    Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.